Cabergoline treatment of risperidone-induced hyperprolactinemia: A pilot study

Journal of Clinical Psychiatry

Volumn 65, Issue 2, 2004, Pages 187-190

  Cavallaro, Roberto ^a   Cocchi, Federica ^a   Angelone, Sara M ^a   Lattuada, Enrico ^a   Smeraldi, Enrico ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE;

ADULT; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; HUMAN; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PSYCHOLOGY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PROLACTIN; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 1842844963     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0207     Document Type: Article

References (16)

1. Wieck A, Haddad P. Hyperprolactinemia caused by antipsychotic drugs. BMJ 2002;324:250-252
2. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002;36:143-164
3. Knegtering H, van der Moolen AEGM, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28:109-123
4. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57-61 (Pubitemid 29047332)
5. Ryan MCM, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002;71:239-257 (Pubitemid 34597188)
6. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case control study. BMJ 2002;325:1-5 (Pubitemid 34864389)
7. Nasrallah HA, Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia. J Clin Psychiatry 2002;63(suppl 13):12-20 (Pubitemid 35471365)
8. Alexiadis M, Whitehorn D, Woodley H, et al. Prolactin elevation with quetiapine [letter]. Am J Psychiatry 2002;159:1608-1609
9. Keller R, Mongini F. Switch to quetiapine in antipsychotic agent-related hyperprolactinemia. Neurol Sci 2002;23:233-235 (Pubitemid 36024567)
10. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-909 (Pubitemid 24299871)
11. Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 2000;23:765-770 (Pubitemid 32041058)
12. Cohen LG, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol 2001;11:435-440 (Pubitemid 34117293)
13. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: A New Comprehensive Rating Scale for Psychotropic Drugs and a Cross-Sectional Study of Side Effects in Neuroleptic-Treated Patients. Acta Psychiatr Scand Suppl 1987;334:1-100 (Pubitemid 17115352)
14. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
15. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28:55-68 (Pubitemid 36332229)
16. Mihara K, Suzuki A, Kondo T, et al. Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 2001;105:271-274 (Pubitemid 32410901)